MENU
+Compare
ANNX
Stock ticker: NASDAQ
AS OF
Dec 23, 04:59 PM (EDT)
Price
$5.28
Change
+$0.05 (+0.96%)
Capitalization
560.68M

ANNX Annexon Forecast, Technical & Fundamental Analysis

a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain

Industry Biotechnology
ANNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ANNX with price predictions
Dec 23, 2024

ANNX's RSI Oscillator ascends from oversold territory

The RSI Indicator for ANNX moved out of oversold territory on December 16, 2024. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 35 similar instances when the indicator left oversold territory. In of the 35 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 19, 2024. You may want to consider a long position or call options on ANNX as a result. In of 69 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ANNX just turned positive on December 16, 2024. Looking at past instances where ANNX's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ANNX advanced for three days, in of 248 cases, the price rose further within the following month. The odds of a continued upward trend are .

ANNX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The 10-day moving average for ANNX crossed bearishly below the 50-day moving average on November 15, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANNX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ANNX entered a downward trend on December 23, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.698) is normal, around the industry mean (14.519). P/E Ratio (0.000) is within average values for comparable stocks, (86.885). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.760). ANNX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (0.000) is also within normal values, averaging (257.834).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ANNX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ANNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ANNX is expected to report earnings to rise 7.32% to -26 cents per share on March 20

Annexon ANNX Stock Earnings Reports
Q4'24
Est.
$-0.27
Q3'24
Beat
by $0.01
Q2'24
Est.
$-0.23
Q1'24
Beat
by $0.13
Q4'23
Beat
by $0.09
The last earnings report on November 14 showed earnings per share of -25 cents, beating the estimate of -25 cents. With 1.21M shares outstanding, the current market capitalization sits at 560.68M.
A.I. Advisor
published General Information

General Information

a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
1400 Sierra Point Parkway
Phone
+1 650 822-5500
Employees
71
Web
https://www.annexonbio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AMKIX11.570.09
+0.78%
American Century Emerging Markets I
JNVMX13.930.08
+0.58%
JPMorgan Developed International ValueR6
MFRJX58.530.30
+0.52%
MFS Research R4
GDEUX22.89N/A
N/A
Goldman Sachs U.S. Equity ESG R6
JSPJX19.40N/A
N/A
Jackson Square Large-Cap Growth Inv

ANNX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ANNX has been loosely correlated with MGTX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ANNX jumps, then MGTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANNX
1D Price
Change %
ANNX100%
+0.96%
MGTX - ANNX
44%
Loosely correlated
-0.98%
FULC - ANNX
40%
Loosely correlated
+7.59%
DNTH - ANNX
40%
Loosely correlated
-2.61%
FDMT - ANNX
38%
Loosely correlated
-6.81%
XENE - ANNX
38%
Loosely correlated
-1.27%
More